TABLE 1

Susceptibilities to azole drugs conferred by expression of native and recombinant LDMs and a cognate Ncp1a

StrainStrain descriptionMIC80
Ergosterol (% wet wt)AMB (μM)FLC (μM)VCZ (nM)VT-1161 (nM)ITC (nM)PCZ (nM)
Y785Host 11.64 ± 0.172.1 ± 0.31.6 ± 0.143 ± 983 ± 12136 ± 9180 ± 27
Y2411Host 22.14 ± 0.062.1 ± 0.21.5 ± 0.242 ± 355 ± 5155 ± 20166 ± 30
Y1031Host 1 PDR5::CgERG112.58 ± 0.032.5 ± 0.35.3 ± 0.8131 ± 8186 ± 20256 ± 46390 ± 49
Y2374Host 1 PDR5::CgERG11 ΔScERG111.81 ± 0.102.5 ± 0.34.5 ± 0.4128 ± 7165 ± 22255 ± 45371 ± 37
Y2372Host 2 PDR5::CaERG112.06 ± 0.141.6 ± 0.23.8 ± 0.483 ± 4137 ± 4235 ± 26352 ± 33
Y2458Host 2 PDR5::CaERG11 ΔScERG112.50 ± 0.141.6 ± 0.22.8 ± 0.248 ± 2103 ± 6234 ± 26321 ± 25
Y2376Host 2 PDR15::CaNCP1A1.70 ± 0.161.5 ± 0.21.4 ± 0.249 ± 543 ± 6131 ± 7120 ± 20
Y2378Host 2 PDR5::CaERG11 PDR15::CaNCP1A2.14 ± 0.091.4 ± 0.14.6 ± 0.2116 ± 4130 ± 7235 ± 26325 ± 50
Y2459Host 2 PDR5::CaERG11 PDR15::CaNCP1A ΔScERG112.54 ± 0.101.6 ± 0.13.8 ± 0.176 ± 4110 ± 11226 ± 24303 ± 41
Y2291Host 2 PDR5::ScERG112.89 ± 0.172.7 ± 0.46.3 ± 0.9166 ± 20205 ± 17314 ± 19376 ± 26
Y2300Host 2 PDR5::ScERG11 ΔScERG112.57 ± 0.162.4 ± 0.45.2 ± 0.8143 ± 23188 ± 16246 ± 9317 ± 32
Y2460Host 2 PDR5::ScNCP10.86 ± 0.031.5 ± 0.22.2 ± 0.278 ± 586 ± 14137 ± 12141 ± 8
Y2461Host 2 PDR5::ScERG113.09 ± 0.012.9 ± 0.25.4 ± 0.4165 ± 20182 ± 22273 ± 13340 ± 10
Y2462Host 2 PDR5::ScNCP1 PDR15::ScERG111.32 ± 0.141.5 ± 0.25.5 ± 0.6214 ± 22173 ± 16223 ± 13289 ± 21
  • a All measurements were carried out in triplicate in 3 separate experiments. The errors are standard deviations.